President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?

President Donald Trump’s tariff strategy is less about trade and more about geopolitical blackmail. By refusing to be rushed ...

President Trump and his administration have been studying new sectoral tariffs that could cover a broad part of the American ...

Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

Amgen Inc. (NASDAQ:AMGN) is one of the high-margin pharma stocks to buy now. HSBC has lowered its price target on Amgen Inc.

President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in ...

Meanwhile, Australian Prime Minister Anthony Albanese has resisted U.S. calls for Australia to raise its defense spending ...

The average consumer could pay 75 percent more for a marketplace plan, according to a KFF analysis, driven by the expiration ...

The expiration of the enhanced ACA premium subsidies at the end of this year is prompting many insurers to hike rates by an ...

Despite former President Donald Trump’s threat of a 200% tariff on imported drugs during a cabinet meeting, pharmaceutical investors have shown surprisingly positive sentiment this week. Despite ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...